Iodine alters gene expression in the MCF7 breast cancer cell line: Evidence for an anti-estrogen effect of iodine

International Journal of Medical Sciences

Volumn 5, Issue 4, 2008, Pages 189-196

  Stoddard II, Frederick R ^a   Brooks, Ari D ^a   Eskin, Bernard A ^a   Johannes, Gregg J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen; Gene expression; Hormone metabolism; Iodine

Indexed keywords

ANTIESTROGEN; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); IODIDE; IODINE; LUGOL; MESSENGER RNA;

ARTICLE; BREAST CANCER; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; ESTROGEN METABOLISM; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

20-HYDROXYSTEROID DEHYDROGENASES; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; ESTROGENS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 47349125602     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kalache A, Vessey MP, McPherson K. Thyroid disease and breast cancer: findings in a large case-control study. Br J Surg 1982, 69:434-435.
2. Smyth PP, Smith DF, McDermott EW, Murray MJ, Geraghty JG, O'Higgins NJ. A direct relationship between thyroid enlargement and breast cancer. J Clin Endocrinol Metab 1996, 81:937-941.
3. Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer 1999, 85:696-705.
4. Eskin BA. Dietary iodine and cancer risk. Lancet 1976, 2:807-808.
5. Eskin BA, Grotkowski CE, Connolly CP, Ghent WR. Different tissue responses for iodine and iodide in rat thyroid and mammary glands. Biol Trace Elem Res 1995, 49:9-19.
6. Funahashi H, Imai T, Tanaka Y, Tobinaga J, Wada M, Morita T, Yamada F, Tsukamura K, Oiwa M, Kikumori T, et al. Suppressive effect of iodine on DMBA-induced breast tumor growth in the rat. J Surg Oncol 1996, 61:209-213.
7. Garcia-Solis P, Alfaro Y, Anguiano B, Delgado G, Guzman RC, Nandi S, Diaz-Munoz M, Vazquez-Martinez O, Aceves C. Inhibition of N-methyl-N- nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion. MolCell Endocrinol 2005, 236:49-57.
8. Ghent WR, Eskin BA, Low DA, Hill LP. Iodine replacement in fibrocystic disease of the breast. Can J Surg 1993, 36:453-460.
9. Kessler JH. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J 2004, 10:328-336.
10. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, Deng HF, Amenta PS, Fineberg S, Pestell RG, Carrasco N. The mammary gland iodide transporter is expressed during lactation and in breast cancer. NatMed 2000, 6:871-878.
11. Strum JM. Effect of iodide-deficiency on rat mammary gland. Virchows ArchB Cell PatholInclMolPathol 1979, 30:209-220.
12. Arroyo-Helguera O, Anguiano B, Delgado G, Aceves C. Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line. Endocr Relat Cancer 2006, 13:1147-1158.
13. Eskin BA, Jacobson HI, Bolmarich V, Murray JA. Breast atypia in altered iodine states: Intracellular changes. Senologia 1977, 2:61-65.
14. Thorpe SM. Increased uptake of iodide by hormone-responsive compared to hormone-independent mammary tumors in GR mice. Int J Cancer 2006, :345-350.
15. Eskin BA, Bartuska DG, Dunn MR, Jacob G, Dratman MB. Mammary gland dysplasia in iodine deficiency. Studies in rats. Jama 1967, 200:691-695.
16. Eskin BA, Shuman R, Krouse T, Merion JA. Rat mammary gland atypia produced by iodine blockade with perchlorate. Cancer Res 1975, 35:2332-2339.
17. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, Deng HF, Amenta PS, Fineberg S, Pestell RG, Carrasco N. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000, 6:871-878.
18. Upadhyay G, Singh R, Agarwal G, Mishra SK, Pal L, Pradhan PK, Das BK, Godbole MM. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat 2003, 77:157-165.
19. Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci U S A 1997, 94:2362-2367.
20. Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, Andre S, Gabius HJ, Khachigian L, Detjen KM, Rosewicz S. Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem 2005, 280:37266-37277.
21. Kaneda S, Nalbantoglu J, Takeishi K, Shimizu K, Gotoh O, Seno T, Ayusawa D. Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem 1990, 265:20277-20284.
22. Bessa M, Joaquin M, Tavner F, Saville MK, Watson RJ. Regulation of the cell cycle by B-Myb. Blood Cells Mol Dis 2001, 27:416-421.
23. Muller-Tidow C, Wang W, Idos GE, Diederichs S, Yang R, Readhead C, Berdel WE, Serve H, Saville M, Watson R, Koeffler HP. Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood 2001, 97:2091-2097.
24. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003, 10:179-186.
25. Kilker RL, Planas-Silva MD. Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. Cancer Res 2006, 66:11478-11484.
26. Wiesenhofer B, Weis C, Humpel C. Glial cell line-derived neurotrophic factor (GDNF) is a proliferation factor for rat C6 glioma cells: evidence from antisense experiments. Antisense Nucleic Acid Drug Dev 2000, 10:311-321.
27. Fujiwaki R, Hata K, Nakayama K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, Sakai E, Miyazaki K. Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes. Int J Cancer 2002, 99:328-335.
28. Tsourouflis G, Theocharis SE, Sampani A, Giagini A, Kostakis A, Kouraklis G. Prognostic and Predictive Value of Thymidylate Synthase Expression in Colon Cancer. Dig Dis Sci 2008;53(5):1289-96.
29. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005, 227:115-124.
30. Rizner TL, Smuc T, Rupreht R, Sinkovec J, Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006, 248:126-135.
31. Maeda T, Hanna AN, Sim AB, Chua PP, Chong MT, Tron VA. GADD45 regulates G2/M arrest, DNA repair, and cell death in keratinocytes following ultraviolet exposure. J Invest Dermatol 2002, 119:22-26.
32. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002, 10:995-1005.
33. Greco A, Gong SS, Ittmann M, Basilico C. Organization and expression of the cell cycle gene, ts11, that encodes asparagine synthetase. Mol Cell Biol 1989, 9:2350-2359.
34. Zhan Q. Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutat Res 2005, 569:133-143.
35. Jia J, Li B, Jin Y, Wang D. Expression, purification, and characterization of human tyrosyl-tRNA synthetase. Protein Expr Purif 2003, 27:104-108.
36. Bange FC, Flohr T, Buwitt U, Bottger EC. An interferon-induced protein with release factor activity is a tryptophanyl-tRNA synthetase. FEBS Lett 1992, 300:162-166.
37. Antonellis A, Lee-Lin SQ, Wasterlain A, Leo P, Quezado M, Goldfarb LG, Myung K, Burgess S, Fischbeck KH, Green ED. Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. J Neurosci 2006, 26:10397-10406.
38. Ciani B, Layfield R, Cavey JR, Sheppard PW, Searle MS. Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone. J Biol Chem 2003, 278:37409-37412.
39. Vogel P, Magert HJ, Cieslak A, Adermann K, Forssmann WG. hDIP - a potential transcriptional regulator related to murine TSC-22 and Drosophila shortsighted (shs) - is expressed in a large number of human tissues. Biochim Biophys Acta 1996, 1309:200-204.
40. Jin VX, Sun H, Pohar TT, Liyanarachchi S, Palaniswamy SK, Huang TH, Davuluri RV. ERTargetDB: an integral information resource of transcription regulation of estrogen receptor target genes. J Mol Endocrinol 2005, 35:225-230.
41. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, et al. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res 2005, 65:6557-6567.
42. Zahid M, Kohli E, Saeed M, Rogan E, Cavalieri E. The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem Res Toxicol 2006, 19:164-172.
43. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002, 62:3691-3697.
44. Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW, Higginbotham SM, Cavalieri EL. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003, 24:697-702.
45. Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK, Rosen EM, Bae I. BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. J Biol Chem 2006, 281:14654-14662.
46. Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia 2004, 9:145-163.
47. Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007, 26:6997-7005.
48. Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005, 65:8009-8016.
49. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004, 90:1942-1948.